The fledgling biosimilars industry is full of uncertainties and nuances that differ by country, therapeutic specialty, and molecule. Securing a positive return on lengthy biosimilar development depends on various factors, but knowledge is the key to success. Gaining physician confidence is critical to securing a meaningful position in developed markets; therefore, understanding their concerns about biosimilar products should be an important part of development and marketing strategies. We conducted primary market research with 548 specialty physicians across the United States and Europe to understand their perspectives on biosimilars and their expectations for use. To understand how physician attitudes vary across therapeutic fields, we surveyed six different types of specialists and posed questions about key topics that will influence uptake. Through our market research, we uncovered the trends in physician perceptions about biosimilars over time and how physicians from different specialties and geographies vary with respect to their opinions on automatic substitution, indication extrapolation, drivers and barriers of uptake, clinical concerns and requirements, and competition from new innovative biologics.

This report is part of the Biosimilars Advisory Service. The Biosimilars Advisory Service provides insight and analysis that are vital to successful business planning in the rapidly evolving biosimilars space. In-depth market analysis is delivered through regular webinars that put major events into context as well as in the form of reports supported by primary market research with physicians and payers. Interactive forecasts allow assessment of market opportunities and strategically focused reports help shape biosimilars’ development and defense strategies. Rely on BioTrends Research Group to keep up-to-date on the biosimilars landscape and poised to maximize opportunities.

Questions Answered in This Report:

  • Understand surveyed physicians’ current level of familiarity with issues associated with biosimilars. How has familiarity with biosimilars evolved over time in Europe and the United States? What are physicians’ opinions on indication extrapolation and how do these attitudes vary by specialty? Are physicians familiar with the pharmacy-level substitution rules in their respective countries?

  • Understand the drivers and barriers of biosimilar use among physicians from different specialties. According to physicians, which factors will stimulate uptake of biosimilars and how does this vary by country? What are physicians’ concerns about using biosimilars and how do they vary by specialty? Which companies do physicians trust most as manufacturers of biosimilars?

  • Understand how physicians’ attitudes translate to expected use of biosimilars. How will physicians adopt biosimilars initially and does this vary by specialty? How will physicians choose between multiple biosimilars of the same reference product? Do physicians expect to use higher-cost biobetters once biosimilars are available?


Markets covered: United States and Europe.

Primary research: Online quantitative survey of 548 specialty physicians in the United States, France, and Germany.

To qualify for participation, surveyed physicians had to meet the following criteria:

- Have worked in clinical practice for a minimum of 3 years and a maximum of 30 years.

- Spend more than 75% of their professional time in clinical practice (with allowances for academic physicians who spend at least 51% of their professional time in clinical practice).

- Prescribe certain biologic drugs (depending on the specialty), including the following: TNF-alpha inhibitors, monoclonal antibodies in oncology, erythropoiesis-stimulating agents (ESAs), granulocyte colony-stimulating factors (G-CSFs), pegylated interferon-alfa, somatropin, insulins.

Author(s): Kate Keeping